Cargando…

How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers

Detalles Bibliográficos
Autores principales:	Chatzidionysiou, Katerina, Delcoigne, Bénédicte, Frisell, Thomas, Hetland, Merete L, Glintborg, Bente, dreyer, lene, Cordtz, René, Zobbe, Kristian, Nordström, Dan, Trokovic, Nina, Aaltonen, Kalle, Provan, Sella Aarrestad, Grondal, Gerdur, Gudbjornsson, Bjorn, Askling, Johan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510630/ https://www.ncbi.nlm.nih.gov/pubmed/32900882 http://dx.doi.org/10.1136/rmdopen-2020-001363

Ejemplares similares

Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries
por: Delcoigne, Benedicte, et al.
Publicado: (2022)

Correction to: Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration
por: Delcoigne, Bénédicte, et al.
Publicado: (2022)

Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration
por: Delcoigne, Bénédicte, et al.
Publicado: (2022)

Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study
por: Cordtz, Rene Lindholm, et al.
Publicado: (2022)

Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis
por: Bower, Hannah, et al.
Publicado: (2023)

Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis
por: Molander, Viktor, et al.
Publicado: (2023)

Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers
por: Delcoigne, Benedicte, et al.
Publicado: (2023)

Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts
por: Westerlind, Helga, et al.
Publicado: (2023)

Siblings of patients with rheumatoid arthritis have an increased mortality rate: a Swedish cohort study
por: Westerlind, Helga, et al.
Publicado: (2020)

Does autoimmune thyroid disease affects rheumatoid arthritis disease activity or response to methotrexate?
por: Waldenlind, Kristin, et al.
Publicado: (2020)

Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy
por: Provan, Sella Aarrestad, et al.
Publicado: (2020)

Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme
por: Frisell, Thomas, et al.
Publicado: (2023)

Comorbidities and treatment patterns in early rheumatoid arthritis: a nationwide Swedish study
por: Tidblad, Liselotte, et al.
Publicado: (2022)

Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking
por: Chatzidionysiou, Katerina, et al.
Publicado: (2022)

Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis
por: Lindström, Ulf, et al.
Publicado: (2019)

Cost-effectiveness of motivational counselling and text reminders in patients with rheumatoid arthritis: results based on a randomised clinical trial
por: Sørensen, Jan, et al.
Publicado: (2022)

Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example
por: Chatzidionysiou, Katerina, et al.
Publicado: (2018)

Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift
por: Chatzidionysiou, Katerina, et al.
Publicado: (2019)

Register-based observational study of associations between inflammatory remission, formal treatment targets and the use of disease-modifying antirheumatic drugs among patients with early rheumatoid arthritis
por: Lindqvist, Joakim, et al.
Publicado: (2023)

Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset
por: Saevarsdottir, Saedis, et al.
Publicado: (2022)

Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors
por: Wadström, Hjalmar, et al.
Publicado: (2020)

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
por: Lauper, Kim, et al.
Publicado: (2022)

Tocilizumab decreases T cells but not macrophages in the synovium of patients with rheumatoid arthritis while it increases the levels of serum interleukin-6 and RANKL
por: Chatzidionysiou, Katerina, et al.
Publicado: (2021)

Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme
por: Yamanaka, Hisashi, et al.
Publicado: (2017)

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
por: Emamikia, Sharzad, et al.
Publicado: (2016)

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
por: Chatzidionysiou, Katerina, et al.
Publicado: (2016)

Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?
por: Mongin, Denis, et al.
Publicado: (2019)

Occupational exposure to asbestos and silica and risk of developing rheumatoid arthritis: findings from a Swedish population-based case-control study
por: Ilar, Anna, et al.
Publicado: (2019)

Is rheumatoid arthritis a risk factor for acute coronary syndrome also among individuals at elevated risk, such as individuals presenting with acute chest pain?
por: Svensson, Per, et al.
Publicado: (2020)

Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: an external validation
por: Ljung, Lotta, et al.
Publicado: (2018)

Association between number and type of different ACPA fine specificities with lung abnormalities in early, untreated rheumatoid arthritis
por: Joshua, Vijay, et al.
Publicado: (2020)

Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors
por: Terslev, L, et al.
Publicado: (2022)

Efficacy of embedded nurse-led versus conventional physician-led follow-up in rheumatoid arthritis: a systematic review and meta-analysis
por: de Thurah, Annette, et al.
Publicado: (2017)

The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries
por: Finckh, A, et al.
Publicado: (2015)

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
por: Lauper, Kim, et al.
Publicado: (2018)

Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: a collaborative matched cohort study from Sweden and Denmark
por: Secher, Anne Emilie Pape, et al.
Publicado: (2022)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011)

No Evidence of Association Between Anti–Tumor Necrosis Factor Treatment and Mortality in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register
por: Lunt, Mark, et al.
Publicado: (2010)

Genome-Wide Association Study of Genetic Predictors of Anti–Tumor Necrosis Factor Treatment Efficacy in Rheumatoid Arthritis Identifies Associations with Polymorphisms at Seven Loci
por: Plant, Darren, et al.
Publicado: (2011)

Association of the HLA–DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis
por: Farragher, Tracey M, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_rtmd0k0pm824j63dqink5tjtat